Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug ...

A cool-mist humidifier can help maintain skin moisture and prevent dryness — plus, the top-rated models from our tests are ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...

CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...

Milestone Pharmaceuticals (MIST) announced the U.S. Food and Drug Administration, FDA, issued a Complete Response Letter, CRL, regarding its ...

(RTTNews) - Milestone Pharmaceuticals (MIST) announced the FDA issued a Complete Response Letter regarding its New Drug Application for CARDAMYST nasal spray, a prescription medication in ...

Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a challenge for Milestone Pharmaceutical in its 22 years. | The FDA has rejected ...

Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results ... administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar ...

RELIEVES DRYNESS: Gentle mist helps to moisturize and relieve dryness in the nose CLEARS CONGESTION: Helps to alleviate congestion and stuffy noses, and flushes irritants from the nasal passage ...

MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray ...